Pharma Focus Europe

Foundation Medicine and Repare Therapeutics Collaborate to Provide Genomic Profiling Services for Clinical Trials and Develop a Companion Diagnostic for Lunresertib

Thursday, June 13, 2024

Foundation Medicine, Inc. has announced a partnership with Repare Therapeutics, a leader in precision oncology, to provide genomic profiling for participants in the ongoing Phase I/Ib MYTHIC study (NCT04855656). This study explores the effects of lunresertib as a standalone treatment or in combination therapies in genetically defined groups of patients. Additionally, the companies are investigating the use of FoundationOne®CDx, a comprehensive genomic profiling test, as a companion diagnostic tool for the lunresertib treatment program.

Lunresertib, a novel oral small molecule inhibitor, targets PKMYT1, a cancer-related protein identified by Repare. The treatment is being evaluated for its potential effectiveness against CCNE1 amplification and alterations in FBXW7 and PPP2R1A across various solid tumors. Preliminary results from Phase 1 trials indicate promising safety and anti-tumor responses, suggesting the potential of lunresertib both as a single therapy and in combination with camonsertib, another investigational ATR inhibitor from Repare.

FoundationOne CDx, which is approved by the FDA, examines over 300 genes associated with cancer to identify genomic changes in tumors using a tissue sample. This test currently supports over 35 indications for companion diagnostics and is a significant component of Foundation Medicine's offerings, encompassing approximately 60% of all U.S. approvals for next-generation sequencing companion diagnostics.

"Reliable companion diagnostics are crucial for effective treatment decisions, especially for patients with limited options," stated Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. "We are pleased to partner with Repare Therapeutics to further the development of this innovative therapy for patients with significant unmet needs."

Foundation Medicine leads the field in cancer molecular profiling, aiming to enhance clinical care and research standards. By collaborating with a wide array of partners in the cancer community, we set high standards in quality, scientific rigor, and regulatory compliance. Our extensive expertise in cancer biology helps doctors make informed treatment decisions and supports researchers in creating new therapies. Every day, we are dedicated to helping our partners discover answers and take action, improving the availability of precision cancer care worldwide.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva